About Tom Wickham

Tom Wickham is Chief Scientific Officer for GentiBio. Tom brings over 25 years of experience in championing diverse drug platforms including cellular, gene, immuno-biologic, and liposomal therapies from Discovery through Registration-directed clinical trials. Tom recently joined GentiBio from Rubius Therapeutics where he was Senior Vice President of Research and Development. At Rubius, Tom pioneered synthetic biology approaches using genetically engineered red cells for autoimmunity, immuno-oncology, and rare disease applications and built a full Discovery and Preclinical organization leading to multiple product programs and two IND filings. Prior to Rubius, he served as Vice President of R&D at Merrimack Pharmaceuticals where he led preclinical through a Phase 2 registrational trial of a targeted liposomal therapy in breast cancer. Prior to Merrimack, Tom was Senior Director of Preclinical Pharmacology and led efforts at EMD Lexigen (now Merck-Serono) to advance immuno-oncology drugs through preclinical development and into Phase I trials. At GenVec, Inc., he led the advancement of a targeted gene delivery platform for oncology, cardiovascular, infectious disease and genetic disease applications. Tom holds a B.S. in chemical/biomedical engineering from Carnegie Mellon University, a Ph.D. in biochemical engineering from Cornell University, and pursued his postdoctoral training at the Scripps Research Institute in the Department of Immunology.